NCT00452023View on ClinicalTrials.gov

Pegasys® in Patients With Myeloproliferative Diseases

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

April 7, 2005

Primary Completion Date

May 26, 2023

Study Completion Date

May 26, 2023

Conditions
Myeloproliferative Disorders
Interventions
DRUG

IFN-alpha2a

Starting dose 90 microgram (mcg) injection under the skin once a week

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00452023 - Pegasys® in Patients With Myeloproliferative Diseases | Biotech Hunter | Biotech Hunter